LMRI

Lumexa Imaging Holdings, Inc.

Nasdaq · Services-Medical Laboratories · Inc. DE · CIK 0002071288
$8.13 -4.35% $781.1M
High Impact Filing (7/10)4 New Institutional Positions
Vol
Market Cap$781.1M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders5 funds
Inst. Value$17.4M
Inst. Activity4 buys / 0 sells
Insider Activity2B / 0S
Insider Net $$476.9K
SEC Reports2
Exchange Nasdaq·Sector Services-Medical Laboratories·Inc. DE·CIK 0002071288·Prev Close $8.50

Recent Activity

May 19, 2026 Insider
BRODNAX BRETT bought 35,000 shares
Director @ $7.25 ($253.8K)
May 14, 2026 Insider
Cooper Henry Lee bought 30,000 shares
Director @ $7.44 ($223.1K)
May 12, 2026 SEC
Lumexa Imaging reported Q1 2026 GAAP EPS of $0.02, a massive miss vs the $0.12 consensus, and revenue of $252.5M slightl
PRESS-RELEASE — Impact 7/10
May 12, 2026 SEC
Lumexa Imaging reported Q1 2026 revenue of $252.5M (+3.1% YoY), slightly above consensus of $251.2M, and GAAP EPS of $0.
8-K — Impact 4/10
Feb 25, 2026 Insider
Walker James Edward Jr. sold 12,414 shares
Principal Accounting Officer @ $0.00 ($0.00)
Inst.
FMR LLC — NEW
681,700 shares ($12.6M)
Inst.
VANGUARD GROUP INC — NEW
230,000 shares ($4.3M)
May 12, 2026 earnings
Lumexa Imaging Announces First Quarter 2026 Results
<p align="justify">RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI),

Price Targets

$17.29 +99.8% upside Strong Buy
Current $8.65 Low $9.00 Median $18.00 High $23.00 7 analysts
$9.00 $23.00

Analyst Ratings

Strong Buy93% buy · 14 analysts
6Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 20, 2026 Barclays MAINTAIN Overweight → Overweight
Apr 14, 2026 Barclays MAINTAIN Overweight → Overweight
Feb 9, 2026 Raymond James UPGRADE Outperform → Strong Buy
Jan 5, 2026 Raymond James INITIATE Outperform
Jan 5, 2026 Barclays INITIATE Overweight

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.14 $0.10 — $0.16 5
Next Q $0.19 $0.16 — $0.21 5
Current FY $0.70 $0.49 — $0.77 291% YoY 5
Next FY $0.89 $0.79 — $1.06 27% YoY 5

Top Institutional Holders

FundValueMove
FMR LLC$12.6MNEW
VANGUARD GROUP INC$4.3MNEW
MORGAN STANLEY$324.4KNEW
TWO SIGMA INVESTMENTS, LP$249.8KNEW
BANK OF AMERICA CORP$111.00

Recent Insider Trades

DateInsiderTypeValue
May 19, 2026BRODNAX BRETTBUY$253.8K
May 14, 2026Cooper HenryBUY$223.1K
Feb 25, 2026Walker JamesA$0.00
5 institutional holders with $17.4M total value (942,739 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN. Net buying activity: 4 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1FMR LLC681,700$12.6M72.3%NEW
2VANGUARD GROUP INC230,000$4.3M24.4%NEW
3MORGAN STANLEY17,533$324.4K1.9%NEW
4TWO SIGMA INVESTMENTS, LP13,500$249.8K1.4%NEW
5BANK OF AMERICA CORP /DE/6$111.000.0%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
FMR LLCNEW681,700$12.6M2025-Q4
VANGUARD GROUP INCNEW230,000$4.3M2025-Q4
MORGAN STANLEYNEW17,533$324.4K2025-Q4
TWO SIGMA INVESTMENTS, LPNEW13,500$249.8K2025-Q4
3 unique insiders with 2 transactions. Net insider value: $476.9K ($476.9K bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 19, 2026BRODNAX BRETTDirectorBUY35,000$7.25$253.8K
May 14, 2026Cooper Henry LeeDirectorBUY30,000$7.44$223.1K
Feb 25, 2026Walker James Edward Jr.Principal Accounting OfficerA12,414$0.00$0.00

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 6 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$17.29 mean target +99.8% upside Strong Buy (1.25)
$9.00 Low $23.00 High
MetricValue
Current Price$8.65
Target Low$9.00
Target Mean$17.29
Target Median$18.00
Target High$23.00
# Analysts7
RecommendationStrong Buy (1.25)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
$0.14 $0.10 $0.16 1↑ 4↓ $0.3B 5
Next Q
2026-09-30
$0.19 $0.16 $0.21 2↑ 2↓ $0.3B 5
Current FY
2026-12-31
$0.70 $0.49 $0.77 290.9% 2↑ 2↓ $1.1B 4.3% 5
Next FY
2027-12-31
$0.89 $0.79 $1.06 27.4% 2↑ 2↓ $1.1B 5.5% 5

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.142
7d ago$0.163-0.021
30d ago$0.000+0.142
60d ago$0.161-0.019
90d ago$0.172-0.030
7 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 7 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 20, 2026 Barclays MAINTAIN Overweight Overweight
Apr 14, 2026 Barclays MAINTAIN Overweight Overweight
Feb 9, 2026 Raymond James UPGRADE Outperform Strong Buy
Jan 5, 2026 Raymond James INITIATE Outperform
Jan 5, 2026 Barclays INITIATE Overweight
Jan 5, 2026 Wells Fargo INITIATE Overweight
Jan 5, 2026 William Blair INITIATE Outperform
Jan 5, 2026 Deutsche Bank INITIATE Buy
Jan 5, 2026 Leerink Partners INITIATE Outperform
Jan 5, 2026 Jefferies INITIATE Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20266710093%
May 1, 20266710093%
Apr 1, 20266710093%
Mar 1, 20264710092%
Feb 1, 20263810092%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 12, 2026
earnings
Lumexa Imaging Announces First Quarter 2026 Results
<p align="justify">RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatien
May 12, 2026
earnings_calendar
LMRI Q1 2026 Earnings Scheduled — 2026-05-12
Apr 28, 2026
earnings
Lumexa Imaging Announces First Quarter 2026 Earnings Conference Call Date
<p align="justify">RALEIGH, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=4pMVR2FjpPusR61cyoQsY1uu-54
Apr 20, 2026
other
Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer
Proven healthcare growth leader to drive disciplined, profitable expansion and scale across Lumexa Imaging’s platform <pre>Proven healthcare growth le
Apr 1, 2026
short_volume
Short Volume: LMRI — 78.8% short (0.6M / 0.8M)
Short: 643,919 | Exempt: 1,000 | TRF Vol: 816,808 | Short Ratio: 78.8% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: LMRI — 71.0% short (0.6M / 0.9M)
Short: 617,716 | Exempt: 57,539 | TRF Vol: 869,833 | Short Ratio: 71.0% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
earnings
Lumexa Imaging Announces Fourth Quarter and Full Year 2025 Results, Reiterates Full Year 2026 Guidance
<p align="justify">RALEIGH, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpati
Mar 26, 2026
short_volume
Short Volume: LMRI — 65.3% short (0.8M / 1.2M)
Short: 805,876 | Exempt: 34,706 | TRF Vol: 1,233,591 | Short Ratio: 65.3% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
earnings_calendar
LMRI Q4 2025 Earnings Scheduled — 2026-03-26
Mar 25, 2026
short_interest
FTD: LMRI — 95,971 shares ($1.0M) failed to deliver
Settlement: 20260325, Price: $10.84, FTD Value: $1,040,325.64, LUMEXA IMAGING HLDGS INC COM
Mar 23, 2026
short_interest
FTD: LMRI — 482,612 shares ($5.7M) failed to deliver
Settlement: 20260323, Price: $11.84, FTD Value: $5,714,126.08, LUMEXA IMAGING HLDGS INC COM